SYLENTIS SAU

Their core work

Sylentis is a Madrid-based pharmaceutical company specializing in nanomedicine development and drug delivery systems. Their work spans the full chain from nanoparticle design for targeted drug delivery through to GMP-compliant manufacturing of polymer-based nanopharmaceuticals. They bring industrial pharmaceutical expertise to research consortia, contributing knowledge on overcoming biological barriers for drug targeting and, more recently, on exploiting bio-based compounds from natural sources. Their participation in both research-focused and manufacturing-scale projects positions them at the translation point between lab discovery and commercial drug production.

What they specialise in

How they've shifted over time

Between 2015 and 2019, Sylentis focused squarely on nanomedicine — drug delivery nanoparticles, overcoming biological barriers, and scaling up nanopharmaceutical production to GMP standards. From 2021 onward, their participation shifted toward bio-based and naturally derived compounds, including biosurfactants and marine siderophores, suggesting a broadening from synthetic nanomedicines into biotechnology-derived active ingredients. This evolution points to a company expanding its pipeline beyond traditional drug delivery into sustainable, nature-sourced bioactive molecules.

Sylentis appears to be diversifying from pure nanopharmaceuticals toward biotechnology-derived compounds, which could make them a valuable partner for projects combining drug delivery expertise with sustainable bio-sourcing.

How they like to work

Sylentis has never coordinated an H2020 project, consistently joining as a participant or third party — indicating they contribute specialized industrial expertise rather than leading research agendas. Despite only three projects, they have worked with 32 unique partners across 14 countries, suggesting they integrate well into large, diverse consortia. Their role pattern points to a company that brings pharmaceutical industry know-how and manufacturing capability to academically driven research teams.

Across just three projects, Sylentis has built connections with 32 partners in 14 countries, reflecting participation in large multi-national consortia with broad European reach.

What sets them apart

Sylentis occupies a relatively rare position as a private pharmaceutical company that bridges nanomedicine research and GMP-scale manufacturing. While many academic groups work on nanoparticle drug delivery, few consortium partners can also contribute pilot-plant production expertise for regulatory-compliant nanopharmaceuticals. Their recent move into bio-based compounds adds a second dimension, making them relevant for projects that need both biotechnology discovery and pharmaceutical translation capacity.

Highlights from their portfolio

• NanoPilot
  Largest funded project (EUR 643K) focused on GMP-compliant pilot plant production — a rare manufacturing-scale contribution in nanopharma research.
• SECRETed
  Marks a strategic pivot into bio-based compounds and biosurfactants, signaling diversification beyond traditional nanomedicine.